Scarica l'app Stockscreener
0.6872
1.58%
-0.011
Precedente Chiudi:
$0.6982
Aprire:
$0.71
Volume 24 ore:
793.59K
Relative Volume:
0.91
Capitalizzazione di mercato:
$77.23M
Reddito:
$3.17M
Utile/perdita netta:
$-36.23M
Rapporto P/E:
-1.681
EPS:
-0.4088
Flusso di cassa netto:
$-17.11M
1 W Prestazione:
-10.90%
1M Prestazione:
-12.23%
6M Prestazione:
-50.91%
1 anno Prestazione:
+4.07%
Intervallo 1D:
$0.6701
$0.7264
Intervallo di 1 settimana:
$0.66
$0.8277
Portata 52W:
$0.387
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Nome
Rani Therapeutics Holdings Inc
Settore
Industria
Telefono
(408) 457-3700
Indirizzo
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.6872 | 77.23M | 3.17M | -36.23M | -17.11M | -0.4088 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Iniziato | Lake Street | Buy |
| 2024-08-02 | Iniziato | Oppenheimer | Outperform |
| 2024-06-14 | Iniziato | Maxim Group | Buy |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-07-27 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-13 | Iniziato | Wedbush | Outperform |
Mostra tutto
Rani Therapeutics Holdings Inc Borsa (RANI) Ultime notizie
PegBio Partners Rani for Oral Metabolic Disease Drugs - AllSci
Rani collaborates with Pegbio on oral drug delivery in obesity - BioWorld News
Why Did Rani Therapeutics (NASDAQ:RANI) Announce New Collaboration? - Kalkine Media
PegBio Teams with Rani Therapeutics to Pursue Oral Metabolic Therapies - TipRanks
Rani Therapeutics, PegBio Collaborate on Oral Delivery of Obesity Drugs - Moomoo
Rani Therapeutics partners with PegBio on obesity drugs - Investing.com
Rani Therapeutics partners with PegBio on obesity drugs By Investing.com - Investing.com Canada
Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates - Yahoo! Finance Canada
Rani Therapeutics (RANI) CFO Nicholas Maestas files initial Form 3 ownership - Stock Titan
Rani Therapeutics | 3: Initial statement of beneficial ownership of securities- Maestas Nicholas - Moomoo
NMAD Stock Price and Chart — NASDAQ:NMAD - TradingView
Price to book forward of Rani Therapeutics Holdings, Inc. – NASDAQ:RANI - TradingView
RANI Technical Analysis & Stock Price Forecast - Intellectia AI
RANI Stock Price, Quote & Chart - ChartMill
Rani Therapeutics | 8-K: Current report - Moomoo
Rani Therapeutics Appoints Nicholas Maestas as New Chief Financial Officer Effective June 29, 2026 - Minichart
New Rani Therapeutics (NASDAQ: RANI) CFO granted options, 2026 inducement plan - Stock Titan
Rani Therapeutics Holdings, Inc. Announces Appointment of Nicholas Maestas as Chief Financial Officer, Effective June 29, 2026 - marketscreener.com
Rani Therapeutics names Nicholas Maestas as CFO - Investing.com
Rani Therapeutics Names Nicholas Maestas CFO - Moomoo
Rani Therapeutics names Nicholas Maestas as CFO By Investing.com - Investing.com Nigeria
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer - marketscreener.com
Press Release: Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer - Moomoo
Price to earnings forward of Rani Therapeutics Holdings, Inc. – NASDAQ:RANI - TradingView
Rani Therapeutics Holdings, Inc. Class A Actuals & Estimates (NASDAQ:RANI) - TradingView
RANI Forecast — Price Target — Prediction for 2027 - TradingView
Rani Therapeutics Holdings Inc (RANI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to sales forward of Rani Therapeutics Holdings, Inc. – NASDAQ:RANI - TradingView
Rani Therapeutics Holdings Inc (RANI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RANI SEC FilingsRani Therapeutics Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Rani Therapeutics Holdings Inc (RANI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rani Therapeutics Holdings Inc (RANI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rani Therapeutics Holdings Inc (RANI) Institutional Confidence - TradingKey
Rani Therapeutics Holdings Inc (RANI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rani Therapeutics Holdings Inc - TradingKey
Rani Therapeutics Holdings Inc (RANI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rani Therapeutics Holdings Inc (RANI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RANI Q1 2026 Earnings: Narrower Loss Drives Optimism Despite Stock PullbackGuidance Update - dars.gov.et
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
RANI Q1 2026 Earnings: Narrower-than-Expected Loss as Pipeline Development AdvancesNew Analyst Coverage - dars.gov.et
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Javadi Alireza - Moomoo
[Form 4] Rani Therapeutics Holdings, Inc. Insider Trading Activity - Stock Titan
Rani Therapeutics (RANI) grants CBO 805,500 stock options - Stock Titan
Rani Therapeutics (NASDAQ: RANI) CTO awarded 805,500 stock options - Stock Titan
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director IMRAN MIR A - Moomoo
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ausiello Dennis A - Moomoo
Director Abraham Bassan receives 123,600 Rani (RANI) stock options - Stock Titan
Rani Therapeutics (NASDAQ: RANI) director receives stock options on 123,600 shares - Stock Titan
Imran Mir A of Rani Therapeutics (NASDAQ: RANI) receives 123,600 stock options - Stock Titan
Director at Rani Therapeutics (RANI) receives 123,600 stock options as compensation award - Stock Titan
Rani Therapeutics (RANI) director granted 123,600 options at $0.9515 exercise price - Stock Titan
Rani Therapeutics Holdings Inc Azioni (RANI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rani Therapeutics Holdings Inc Azioni (RANI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| South Cone Investments Limited | 10% Owner |
Oct 21 '25 |
Sale |
2.77 |
4,000,000 |
11,074,000 |
2,379,194 |
| South Cone Investments Limited | 10% Owner |
Oct 20 '25 |
Sale |
2.41 |
1,923,000 |
4,637,314 |
6,379,194 |
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):